NCT00746681 - Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder | Biotech Hunter

Enrollment

188

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

November 30, 2006

Conditions

Overactive Bladder

Interventions

DRUG

Tolterodine & Pregabalin

Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks

DRUG

Tolterodine

Tolterodine SR, Oral, 4 mg, once daily for 4 weeks

DRUG

Placebo

Placebo, Oral, twice daily for 4 weeks

DRUG

Tolterodine & Pregabalin

Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks

DRUG

Pregabalin

Pregabalin, Oral, 150 mg twice daily for 4 weeks

Trial Locations (23)

5507

Pfizer Investigational Site, Haugesund

7006

Pfizer Investigational Site, Trondheim

97180

Pfizer Investigational Site, Luleå

500 05

Pfizer Investigational Site, Hradec Králové

110 00

Pfizer Investigational Site, Prague

130 00

Pfizer Investigational Site, Prague

140 59

Pfizer Investigational Site, Praha 4 - Krc

401 13

Pfizer Investigational Site, Ústí nad Labem

LT-47144

Pfizer Investigational Site, Kaunas

LT-50009

Pfizer Investigational Site, Kaunas

LT-01118

Pfizer Investigational Site, Vilnius

LT-08661

Pfizer Investigational Site, Vilnius

N-2390

Pfizer Investigational Site, Moelv

Unknown

Pfizer Investigational Site, Martin

901 01

Pfizer Investigational Site, Bratislava

040 11

Pfizer Investigational Site, Košice

909 82

Pfizer Investigational Site, Skalica

601 82

Pfizer Investigational Site, Norrköping

141 86

Pfizer Investigational Site, Stockholm

DD1 9SY

Pfizer Investigational Site, Dundee

BS10 5NB

Pfizer Investigational Site, Bristol

PL6 8DH

Pfizer Investigational Site, Plymouth